Assess whether RWE can replace or only supplement an RCT (7d6f34)

Situation

In a rare-disease team designing a pediatric plan, scientific-advice briefing book is the evidence after a pediatric ethicist objecting to the proposed design. 505(b)(2) development lead has to pick RWE can replace or Only supplement an RCT for this Pharma & Life Sciences FDA Response and Labeling close using scientific-advice briefing book.

Decision

505(b)(2) development lead in a rare-disease team designing a pediatric plan must choose RWE can replace / Only supplement an RCT using scientific-advice briefing book after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• Scientific-advice briefing book reads as RWE can replace once a pediatric ethicist objecting to the proposed design is lined up to the same Pharma & Life Sciences population.
• Scientific-advice briefing book is closer to Only supplement an RCT after a pediatric ethicist objecting to the proposed design; RWE can replace would over-claim this FDA Response and Labeling extract.
• A dual reading is still live in scientific-advice briefing book for 505(b)(2) development lead in a rare-disease team designing a pediatric plan.
• Scientific-advice briefing book is missing the fact 505(b)(2) development lead needs after a pediatric ethicist objecting to the proposed design; stop this Pharma & Life Sciences close.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against a pediatric ethicist objecting to the proposed design and write the one fact that would move RWE can replace or for 505(b)(2) development lead.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / FDA Response and Labeling packet (scientific-advice briefing book after a pediatric ethicist objecting to the proposed design). The follow-on FDA Response and Labeling action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.